Valuation: Agenus Inc.

Market Cap 313M 281M 263M 238M 447M 29.78B 450M 3.15B 1.23B 15.45B 1.17B 1.15B 49.7B P/E 2026 *
28.2x
P/E 2027 * -14.7x
Enterprise Value 313M 281M 263M 238M 447M 29.78B 450M 3.15B 1.23B 15.45B 1.17B 1.15B 49.7B EV / Sales 2026 *
2.5x
EV / Sales 2027 * 2.7x
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -
1 day-5.04%
1 week-13.08%
Current month-33.74%
1 month-7.71%
3 months+29.53%
6 months+39.41%
Current year+109.55%
1 week 6.53
Extreme 6.53
7.79
1 month 6.53
Extreme 6.53
10.31
Current year 2.71
Extreme 2.71
10.31
1 year 2.71
Extreme 2.71
10.31
3 years 1.38
Extreme 1.38
23.2
5 years 1.38
Extreme 1.38
111.4
10 years 1.38
Extreme 1.38
135.8
Manager TitleAgeSince
Chief Executive Officer 73 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 73 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Director

1,179 0.0026%
01/10/26 Free

Director

4,443 0.0098%
10/08/26 Free

Chief Executive Officer

1,971,500 4.4054%
Change 5-day change 1-year change 3-year change Capi.($)
-5.04%-13.08%+65.74%-70.09% 313M
-2.01%-7.86%+54.60%+70.97% 70.44B
+3.84%-11.02%+8.59%+58.77% 50.31B
+3.35%+1.42%+11.85%+37.39% 47.51B
+0.81%+1.62%+28.10%+31.82% 42.91B
+2.96%-3.01%+310.17%+471.01% 40.39B
+0.99%-3.05%+9.97%+102.90% 39.69B
+0.06%-1.43%+10.47%+43.27% 30.59B
-2.95%-14.09%+37.94%+1.30% 26.8B
+0.04%-6.36%-13.08%-8.02% 22.36B
Average +0.19%-6.51%+52.43%+73.93% 37.13B
Weighted average by Cap. +0.86%-5.45%+53.96%+95.24%

Financials

2026 *2027 *
Net sales 125M 113M 105M 95.21M 179M 11.91B 180M 1.26B 492M 6.18B 470M 460M 19.89B 116M 104M 97.3M 88.19M 166M 11.04B 167M 1.17B 456M 5.73B 435M 426M 18.42B
Net income 39.4M 35.42M 33.06M 29.96M 56.25M 3.75B 56.6M 397M 155M 1.95B 148M 145M 6.26B -28.55M -25.67M -23.95M -21.71M -40.76M -2.72B -41.01M -287M -112M -1.41B -107M -105M -4.54B
Net Debt - -
Projected Income Statement - Annual - Agenus Inc.
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
14/10/26 $6.570 -5.47% 423,398
13/10/26 $6.950 -6.46% 995,561
12/10/26 $7.430 -3.13% 572,490
09/10/26 $7.670 +1.72% 710,289
08/10/26 $7.540 -0.40% 1,215,018
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Agenus Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.950USD
Average target price
26.33USD
Spread / Average Target
+278.90%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Agenus Inc.
  1. Stock Market
  2. Stocks
  3. AGEN Stock